🚀 VC round data is live in beta, check it out!
Convatec Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Convatec Group and similar public comparables like Bruker, Caris Life Sciences, Getinge, Bausch + Lomb and more.
Convatec Group Overview
About Convatec Group
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
Founded
2016
HQ
Employees
10.5K
Website
Financials (LTM)
EV
$8B
Convatec Group Financials
Convatec Group reported last 12-month revenue of $2B and EBITDA of $660M.
In the same LTM period, Convatec Group generated $1B in gross profit, $660M in EBITDA, and $370M in net income.
Revenue (LTM)
Convatec Group P&L
In the most recent fiscal year, Convatec Group reported revenue of $2B and EBITDA of $645M.
Convatec Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 56% | XXX | XXX | XXX |
| EBITDA | $660M | XXX | $645M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 26% | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $370M | XXX | $358M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | — | — | $1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Convatec Group Stock Performance
Convatec Group has current market cap of $6B, and enterprise value of $8B.
Market Cap Evolution
Convatec Group's stock price is $3.24.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8B | $6B | 1.4% | XXX | XXX | XXX | $0.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialConvatec Group Valuation Multiples
Convatec Group trades at 3.1x EV/Revenue multiple, and 11.8x EV/EBITDA.
EV / Revenue (LTM)
Convatec Group Financial Valuation Multiples
As of April 21, 2026, Convatec Group has market cap of $6B and EV of $8B.
Equity research analysts estimate Convatec Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Convatec Group has a P/E ratio of 17.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | 11.8x | XXX | 12.1x | XXX | XXX | XXX |
| EV/EBIT | 13.9x | XXX | 14.3x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | 5.7x | XXX | XXX | XXX |
| P/E | 17.1x | XXX | 17.7x | XXX | XXX | XXX |
| EV/FCF | 29.9x | XXX | 27.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Convatec Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Convatec Group Margins & Growth Rates
Convatec Group's revenue in the last 12 month grew by 6%.
Convatec Group's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Convatec Group's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Convatec Group's rule of X is 41% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Convatec Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 41% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 27% | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | 8% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Convatec Group Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Convatec Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Bruker | XXX | XXX | XXX | XXX | XXX | XXX |
| Caris Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Getinge | XXX | XXX | XXX | XXX | XXX | XXX |
| Bausch + Lomb | XXX | XXX | XXX | XXX | XXX | XXX |
| Shimadzu | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Convatec Group M&A Activity
Convatec Group acquired XXX companies to date.
Last acquisition by Convatec Group was on XXXXXXXX, XXXXX. Convatec Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Convatec Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialConvatec Group Investment Activity
Convatec Group invested in XXX companies to date.
Convatec Group made its latest investment on XXXXXXXX, XXXXX. Convatec Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Convatec Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Convatec Group
| When was Convatec Group founded? | Convatec Group was founded in 2016. |
| Where is Convatec Group headquartered? | Convatec Group is headquartered in United Kingdom. |
| How many employees does Convatec Group have? | As of today, Convatec Group has over 10K employees. |
| Is Convatec Group publicly listed? | Yes, Convatec Group is a public company listed on London Stock Exchange. |
| What is the stock symbol of Convatec Group? | Convatec Group trades under CTEC ticker. |
| When did Convatec Group go public? | Convatec Group went public in 2016. |
| Who are competitors of Convatec Group? | Convatec Group main competitors are Bruker, Caris Life Sciences, Getinge, Bausch + Lomb. |
| What is the current market cap of Convatec Group? | Convatec Group's current market cap is $6B. |
| What is the current revenue of Convatec Group? | Convatec Group's last 12 months revenue is $2B. |
| What is the current revenue growth of Convatec Group? | Convatec Group revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Convatec Group? | Current revenue multiple of Convatec Group is 3.1x. |
| Is Convatec Group profitable? | Yes, Convatec Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Convatec Group? | Convatec Group's last 12 months EBITDA is $660M. |
| What is Convatec Group's EBITDA margin? | Convatec Group's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Convatec Group? | Current EBITDA multiple of Convatec Group is 11.8x. |
| What is the current FCF of Convatec Group? | Convatec Group's last 12 months FCF is $260M. |
| What is Convatec Group's FCF margin? | Convatec Group's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Convatec Group? | Current FCF multiple of Convatec Group is 29.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.